Clinical Trials Logo

Carcinoma, Ovarian Epithelial clinical trials

View clinical trials related to Carcinoma, Ovarian Epithelial.

Filter by:

NCT ID: NCT03924882 Recruiting - Ovarian Cancer Clinical Trials

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Start date: April 25, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and toxicity of anlotinib in patients with platinum resistant or refractory ovarian cancer

NCT ID: NCT03916679 Recruiting - Ovarian Cancer Clinical Trials

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Start date: April 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory epithelial ovarian cancer.

NCT ID: NCT03907527 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.

NCT ID: NCT03899610 Recruiting - Clinical trials for Ovarian Cancer Stage IV

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

KGOG3046
Start date: July 4, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this trial is to evaluate the synergistic effects of durvalumab and tremelimumab plus chemotherapy in advanced-stage ovarian cancer. Ovarian cancer is the deadliest gynecologic cancer. The current standard therapy is surgical cytoreduction followed by taxane-platinum combination chemotherapy. However, most patients with advanced-stage ovarian cancer will experience a relapse of disease. Therefore, there is an urgent need to improve outcomes of patients with this aggressive cancer. Research hypothesis: Adding durvalumab and tremelimumab to current neoadjuvant chemotherapy (front-line therapy) in advanced-stage ovarian cancer can increase response rate and improve patient's outcome such as progression-free survival and overall survival with minimal effects on safety.

NCT ID: NCT03895788 Recruiting - Ovarian Cancer Clinical Trials

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

Open-label, cohort study to determine the safety and tolerability of the combination of daily niraparib and daily brivanib for one 28-day cycle in patients with advanced ovarian cancer.

NCT ID: NCT03872947 Recruiting - Colorectal Cancer Clinical Trials

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Start date: April 26, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

NCT ID: NCT03862677 Recruiting - Clinical trials for Epithelial Ovarian Cancer

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

IMPrOVE
Start date: August 15, 2020
Phase:
Study type: Observational

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

NCT ID: NCT03842982 Recruiting - Ovarian Cancer Clinical Trials

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

CHIPPI
Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.

NCT ID: NCT03827837 Recruiting - Cervical Cancer Clinical Trials

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Start date: January 23, 2019
Phase: Phase 2
Study type: Interventional

Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase inhibitor Famitinib in subjects with advanced RCC/UC/CC/EC and recurrent OC. chort1: Renal Cell Carcinoma (RCC) chort2: Urothelial Carcinoma(UC) chort3: Ovarian Cancer (OC) chort4: Cervical Cancer (CC) chort5: Endometrial Cancer (EC)

NCT ID: NCT03814447 Recruiting - Ovarian Cancer Clinical Trials

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Start date: August 16, 2019
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer